06:49 EST BioNTech (BNTX) cuts FY25 CapEx view to EUR 200M-EUR 250M from EUR 250M-EUR 350M
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BNTX Upcoming Earnings Report: What to Expect?
- BioNTech’s Latest Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment
- Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment
- Bristol-Myers Squibb and BioNTech Launch New Colorectal Cancer Study
- Bristol-Myers Squibb and BioNTech’s New Study: A Potential Game-Changer in Cancer Treatment?